studies

breast cancer (BC), trastuzumab deruxtecan vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsDESTINY Breast03, 2022 0.55 [0.36; 0.85] DESTINY-Breast04, 2022 0.64 [0.49; 0.84] 0.61[0.49; 0.77]DESTINY Breast03, 2022, DESTINY-Breast04, 202220%557moderatenot evaluable progression or deaths (PFS)detailed resultsDESTINY Breast03, 2022 0.28 [0.22; 0.36] DESTINY-Breast04, 2022 0.50 [0.40; 0.63] 0.38[0.21; 0.66]DESTINY Breast03, 2022, DESTINY-Breast04, 2022291%557moderatenot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-06-26 18:34 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 64,370,336,147,145,355,337,146,317,4,319,144,356,351,357,352,354,353,358,359,324,142,305,306,98,96,269,60,143,270,140,240,3 - treatments: 1233